CTLA4 and enteritis: Previous studies have found that I3A can alleviate immune‐associated enteritis, an adverse reaction of immune checkpoint Anti‐CTLA‐4 antibody therapy.[51] At the same time, this study also suggested that I3A did not affect the therapeutic effect of Anti‐CTLA‐4 antibody, but we noted that the dose and route of I3A administration in this study (18 mg/kg, p.o.)was different from that of our study (50 mg/kg i.p.).